RecruitingTransthyretin Amyloidosis Cardiomyopathy (ATTR-CM)AmyloidosisAmyloid Cardiomyopathy
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
Sponsor: Eidos Therapeutics, a BridgeBio company
Where it's recruiting
Missouri
St Louis
Source: ClinicalTrials.gov · NCT07695701 · last updated 2026-07-29